“Our focus at Repertoire Immune Medicines is to decipher the immune system, specifically looking at human subject-derived antigen-T cell receptor (TCR) codes from healthy or diseased tissues, which dictates T cell activation or exhaustion.
At the helm is Chief Executive Officer John Cox, who most recently led the spin-off of Bioverativ (BIIV) from Biogen (BIIB), and its growth and successful acquisition by Sanofi (SNY). Repertoire Immune Medicines was then formed by combining two Flagship companies – the innovative and proprietary immune decoding platforms of Cogen Immune Medicines and the immuno-oncology platforms of Torque Therapeutics to create a fully integrated Immune Medicines company. Darrell Irvine’s lab at MIT, focused on using autologous T cells to direct potent immune modulators to the tumor microenvironment. In parallel, another Flagship origination group, led by Doug Cole, M.D., General Partner of Flagship Pioneering, and based on the cytokine binding work from Prof. One origination group, led by David Berry, M.D., Ph.D., General Partner of Flagship Pioneering, focused on systematically unlocking antigen specific immune control.
#Repertoire therapeutics how to
The journey for Repertoire Immune Medicines commenced when Flagship Labs’ scientists contemplated how to rationally and efficiently direct the power of our T cells for therapeutics and cures. “Repertoire’s approach could yield a comprehensive decoding of dominant antigens and T cell receptors for different T1D patient subgroups, which remains a challenge and key priority for T1D drug discovery and development.” “We are excited by Repertoire Immune Medicines’ world-class team and believe the highly innovative platform can enable a range of different therapies to change the trajectory for people with T1D,” said Katie Ellias, Managing Director at the JDRF T1D Fund.
With nearly $100 million in assets under management, the T1D Fund has invested in 19 innovative companies in areas that include therapeutics, devices, vaccines and diagnostics. Launched in December 2016 to accelerate growth in the T1D investment market, the T1D Fund is the first scale, mission-driven venture philanthropy fund focused on commercial investments in companies delivering solutions to patients living with or at risk of developing the autoimmune disease.
Terms of the private financing were not disclosed. The investment from the JDRF T1D Fund will enable the company to utilize its core platforms to discover new antigens and T cell receptors in hopes of advancing the development of treatments and cures for T1D. & BOSTON-( BUSINESS WIRE)- Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).
0 kommentar(er)
